GenioDx will have the exclusive right to market, sell and...

GenioDx will have the exclusive right to market, sell and distribute Anteo's range of Anteobind products in China, specifically within the Chinese in-vitro diagnostics (IVD) market and targeting market leading Chinese manufacturers of point of care (POC) and diagnostics products according to Anteo.

They have agreed to conduct a comprehensive promotional  campaign targeting prospective Chinese customers with the purpose of gathering market based feedback to further refine the value proposition of Anteo's products.

After a mutually - agreed initial review, GenioDx will then undertake a full - scale countrywide product launch to prospective customers with the aim of capturing early evaluators of Anteo's products and to establish a business plan for next year.

Use of the words promotional, targeting, prospective customers IMO indicates that there is a hell of a lot of work to be done yet.

Even if they do establish a decent sizable customer base, refine the value proposition of Anteo's products and establish a business plan accordingly it will be at least 12 to 18 months before any significant revenue rolls into the Anteo coffers.

It is speculative and subject to a lot of variables whether Anteo and GenioDx will even arrive at a mutually agreeable deal at the conclusion of their respective due diligence.